Dong Woo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dong Woo Lee has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Yoon Jeong Park
Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), Seoul, 03127, Republic of Korea; Department of Dental Regenerative Biotechnology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea
5 shared publications - Chong-Pyoung Chung
Central Research Institute Nano Intelligent Biomedical Engineering Corporation (NIBEC) Seoul Korea
3 shared publications - Hee-Seung Han
Department of Periodontology Korea University Anam Hospital Seoul Republic of Korea
3 shared publications - Jue-Yeon Lee
Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), School of Dentistry, Seoul National University, Seoul 03080, Korea
3 shared publications - Young-Dan Cho
Department of Periodontology, School of Dentistry and Dental Research Institute Seoul National University and Seoul National University Dental Hospital Seoul Republic of Korea
3 shared publications - Chong Pyung Chung
Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), Seoul, 03127, Republic of Korea; Department of Periodontology, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Elsevier in Biomaterials
- Vol. 338 (Pt A) , 124591
BMP9-loaded collagen scaffold promotes periodontal regeneration via microenvironmental modulation of PDLSCs and macrophages
- 31 August 2026
- Published by Elsevier in Biomaterials
- Vol. 338 (Pt A) , 124591
Open AccessBMP9-loaded collagen scaffold promotes periodontal regeneration via microenvironmental modulation of PDLSCs and macrophages
- Open Access
- 7 July 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124438
Lymph node-targeted mRNA delivery of fine-tuned peptide-nanocomplexes for SARS-CoV-2 Vaccination
- 7 July 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124438
Open AccessLymph node-targeted mRNA delivery of fine-tuned peptide-nanocomplexes for SARS-CoV-2 Vaccination
- Open Access
- 10 March 2026
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 28 (2) , e70135
Bone Morphogenetic Protein ( BMP ) 9 Outperforms BMP2 in Osteogenesis and Osseointegration: In Vitro and In Vivo
Objectives: This study compared the osteogenic mechanisms and preclinical efficacy of bone morphogenetic protein 9 (BMP9) and BMP2 in vitro and in a beagle peri‐implant defect model in vivo. Materials and Methods: In vitro, MC3T3‐E1 preosteoblasts were treated with BMP2 or BMP9 to assess osteogenic gene expression ( Col1, Runx2, Alp, Ocn ) by real‐time PCR, Smad1/5/9 phosphorylation by western blotting, and osteogenesis by alkaline phosphatase (ALP) and Alizarin Red S staining. In vivo, saddle‐type peri‐implant defects were created in beagle mandibles and treated with a collagenated xenograft matrix with or without BMP2 or BMP9 (150 μg/site). After 8 weeks, implant stability, micro‐CT, histomorphometry, and osseointegration parameters were analyzed. Results: BMP9 significantly enhanced osteogenic gene expression, Smad1/5/9 phosphorylation, ALP activity, and mineralization compared to BMP2. In vivo, BMP9 yielded the highest implant stability values, greater defect fill, and higher bone volume fraction, bone mineral density, and bone‐to‐implant contact. Conclusions: BMP9 showed stronger osteoinductive potential than BMP2, resulting in improved bone regeneration and osseointegration. These findings suggest that BMP9 is a promising growth factor for improving dental implant outcomes.
- 10 March 2026
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 28 (2) , e70135
Open AccessBone Morphogenetic Protein ( BMP ) 9 Outperforms BMP2 in Osteogenesis and Osseointegration: In Vitro and In Vivo
Objectives: This study compared the osteogenic mechanisms and preclinical efficacy of bone morphogenetic protein 9 (BMP9) and BMP2 in vitro and in a beagle peri‐implant defect model in vivo. Materials and Methods: In vitro, MC3T3‐E1 preosteoblasts were treated with BMP2 or BMP9 to assess osteogenic gene expression ( Col1, Runx2, Alp, Ocn ) by real‐time PCR, Smad1/5/9 phosphorylation by western blotting, and osteogenesis by alkaline phosphatase (ALP) and Alizarin Red S staining. In vivo, saddle‐type peri‐implant defects were created in beagle mandibles and treated with a collagenated xenograft matrix with or without BMP2 or BMP9 (150 μg/site). After 8 weeks, implant stability, micro‐CT, histomorphometry, and osseointegration parameters were analyzed. Results: BMP9 significantly enhanced osteogenic gene expression, Smad1/5/9 phosphorylation, ALP activity, and mineralization compared to BMP2. In vivo, BMP9 yielded the highest implant stability values, greater defect fill, and higher bone volume fraction, bone mineral density, and bone‐to‐implant contact. Conclusions: BMP9 showed stronger osteoinductive potential than BMP2, resulting in improved bone regeneration and osseointegration. These findings suggest that BMP9 is a promising growth factor for improving dental implant outcomes.
- Open Access
- 3 February 2026
- Published by Wiley in Journal of Periodontal Research
- Vol. 61 (5) , 586-605
A Multifunctional β‐Defensin‐3 Mimetic Peptide Modulates Host–Biofilm Interactions and Reduces Bone Loss in Periodontitis
Aim: This study evaluated the potential of a beta‐defensin‐3 mimetic peptide (BDMP), a synthetic cell‐penetrating peptide with antimicrobial and immunomodulatory properties, as an adjunctive therapeutic approach for periodontitis. Methods: BDMP was formulated in a hydroxyethyl cellulose (HEC) gel and assessed for binding affinity, release kinetics, and ability to penetrate cells and gingival tissues. Anti‐inflammatory and osteoclast‐related signaling pathways were examined in vitro using RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). Effects on osteogenic recovery were evaluated in periodontal ligament stem cells (PDLSCs) under inflammatory conditions. Antimicrobial activity against multispecies biofilms was analyzed by confocal microscopy. In a ligature‐induced experimental periodontitis model in beagle dogs, BDMP gel was compared with a subgingival instrumentation (SI)‐only (standard‐of‐care) control, and minocycline gel was included as an active adjunctive comparator. Clinical parameters, inflammatory markers, microbial load, radiographs, micro‐CT images, and histology were evaluated. Results: In vitro, BDMP reduced histone deacetylase 5 (HDAC5) phosphorylation and attenuated downstream NF‐κB–associated inflammatory signaling without altering upstream kinase activity. BDMP decreased osteoclast differentiation, reduced inflammatory cytokine transcription, and partially restored osteogenic capacity in LPS‐stimulated PDLSCs. BDMP also demonstrated broad‐spectrum antimicrobial activity and disrupted mature multispecies biofilms. In vivo, BDMP resulted in greater reductions in gingival inflammation, bleeding, IL‐1β levels, and oral spirochetes over 12 weeks compared with the SI‐only control. Radiographic images provided qualitative support for reduced bone loss, which was corroborated by micro‐CT and histology, indicating attenuation of alveolar bone resorption. When compared with the combination of SI and minocycline arm, BDMP showed comparable or greater improvements in several inflammatory and microbiological parameters. Conclusion: BDMP exhibited sustained antimicrobial and anti‐inflammatory activity and attenuated bone loss in a beagle periodontitis model when used alongside standard SI therapy. These findings support BDMP as a promising adjunctive therapeutic candidate for managing periodontal inflammation and biofilm‐associated disease, although further studies are needed to confirm long‐term safety and to define its mechanistic contributions to periodontal tissue preservation.
- 3 February 2026
- Published by Wiley in Journal of Periodontal Research
- Vol. 61 (5) , 586-605
Open AccessA Multifunctional β‐Defensin‐3 Mimetic Peptide Modulates Host–Biofilm Interactions and Reduces Bone Loss in Periodontitis
Aim: This study evaluated the potential of a beta‐defensin‐3 mimetic peptide (BDMP), a synthetic cell‐penetrating peptide with antimicrobial and immunomodulatory properties, as an adjunctive therapeutic approach for periodontitis. Methods: BDMP was formulated in a hydroxyethyl cellulose (HEC) gel and assessed for binding affinity, release kinetics, and ability to penetrate cells and gingival tissues. Anti‐inflammatory and osteoclast‐related signaling pathways were examined in vitro using RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). Effects on osteogenic recovery were evaluated in periodontal ligament stem cells (PDLSCs) under inflammatory conditions. Antimicrobial activity against multispecies biofilms was analyzed by confocal microscopy. In a ligature‐induced experimental periodontitis model in beagle dogs, BDMP gel was compared with a subgingival instrumentation (SI)‐only (standard‐of‐care) control, and minocycline gel was included as an active adjunctive comparator. Clinical parameters, inflammatory markers, microbial load, radiographs, micro‐CT images, and histology were evaluated. Results: In vitro, BDMP reduced histone deacetylase 5 (HDAC5) phosphorylation and attenuated downstream NF‐κB–associated inflammatory signaling without altering upstream kinase activity. BDMP decreased osteoclast differentiation, reduced inflammatory cytokine transcription, and partially restored osteogenic capacity in LPS‐stimulated PDLSCs. BDMP also demonstrated broad‐spectrum antimicrobial activity and disrupted mature multispecies biofilms. In vivo, BDMP resulted in greater reductions in gingival inflammation, bleeding, IL‐1β levels, and oral spirochetes over 12 weeks compared with the SI‐only control. Radiographic images provided qualitative support for reduced bone loss, which was corroborated by micro‐CT and histology, indicating attenuation of alveolar bone resorption. When compared with the combination of SI and minocycline arm, BDMP showed comparable or greater improvements in several inflammatory and microbiological parameters. Conclusion: BDMP exhibited sustained antimicrobial and anti‐inflammatory activity and attenuated bone loss in a beagle periodontitis model when used alongside standard SI therapy. These findings support BDMP as a promising adjunctive therapeutic candidate for managing periodontal inflammation and biofilm‐associated disease, although further studies are needed to confirm long‐term safety and to define its mechanistic contributions to periodontal tissue preservation.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Periodontal & Implant Science
- Vol. 56 (5) , 417
BMP9 promotes peri-implant osseointegration in beagle defects
Han HS, et al. J Periodontal Implant Sci. 2026 ;56:e14. https://doi.org/10.5051/jpis.2505500275
- 1 January 2026
- Published by XMLink in Journal of Periodontal & Implant Science
- Vol. 56 (5) , 417
Open AccessBMP9 promotes peri-implant osseointegration in beagle defects
Han HS, et al. J Periodontal Implant Sci. 2026 ;56:e14. https://doi.org/10.5051/jpis.2505500275